These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27568206)

  • 21. GSK3β Controls mTOR and Prosurvival Signaling in Neurons.
    Urbanska M; Gozdz A; Macias M; Cymerman IA; Liszewska E; Kondratiuk I; Devijver H; Lechat B; Van Leuven F; Jaworski J
    Mol Neurobiol; 2018 Jul; 55(7):6050-6062. PubMed ID: 29143288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization.
    Hayashi K; Michiue H; Yamada H; Takata K; Nakayama H; Wei FY; Fujimura A; Tazawa H; Asai A; Ogo N; Miyachi H; Nishiki T; Tomizawa K; Takei K; Matsui H
    Sci Rep; 2016 Mar; 6():23372. PubMed ID: 26988603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
    Charest A; Wilker EW; McLaughlin ME; Lane K; Gowda R; Coven S; McMahon K; Kovach S; Feng Y; Yaffe MB; Jacks T; Housman D
    Cancer Res; 2006 Aug; 66(15):7473-81. PubMed ID: 16885344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
    Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of Discoidin Domain Receptor 1 with a 14-3-3-Beclin-1-Akt1 Complex Modulates Glioblastoma Therapy Sensitivity.
    Vehlow A; Klapproth E; Jin S; Hannen R; Hauswald M; Bartsch JW; Nimsky C; Temme A; Leitinger B; Cordes N
    Cell Rep; 2019 Mar; 26(13):3672-3683.e7. PubMed ID: 30917320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fangchinoline suppresses the growth and invasion of human glioblastoma cells by inhibiting the kinase activity of Akt and Akt-mediated signaling cascades.
    Guo B; Xie P; Su J; Zhang T; Li X; Liang G
    Tumour Biol; 2016 Feb; 37(2):2709-19. PubMed ID: 26408176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Regulation of PI3K-Akt-GSK3β signaling pathway in U251 cells by risperidone].
    Liang L; Wang Y; Wei J; Gu X; Xiang B; Ma X; Li T
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Dec; 31(6):693-7. PubMed ID: 25449069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).
    Khabibov M; Garifullin A; Boumber Y; Khaddour K; Fernandez M; Khamitov F; Khalikova L; Kuznetsova N; Kit O; Kharin L
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35445737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the Akt-pathway to improve radiosensitivity in glioblastoma.
    Narayan RS; Fedrigo CA; Stalpers LJ; Baumert BG; Sminia P
    Curr Pharm Des; 2013; 19(5):951-7. PubMed ID: 22973963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrin-linked kinase is an essential mediator for T-cadherin-dependent signaling via Akt and GSK3beta in endothelial cells.
    Joshi MB; Ivanov D; Philippova M; Erne P; Resink TJ
    FASEB J; 2007 Oct; 21(12):3083-95. PubMed ID: 17485554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells.
    Skurk C; Maatz H; Rocnik E; Bialik A; Force T; Walsh K
    Circ Res; 2005 Feb; 96(3):308-18. PubMed ID: 15662032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.
    Höland K; Salm F; Arcaro A
    Curr Cancer Drug Targets; 2011 Oct; 11(8):894-918. PubMed ID: 21861842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.
    Chen HY; Lin LT; Wang ML; Lee SH; Tsai ML; Tsai CC; Liu WH; Chen TC; Yang YP; Lee YY; Chang YL; Huang PI; Chen YW; Lo WL; Chiou SH; Chen MT
    Oncotarget; 2016 Jul; 7(27):42485-42501. PubMed ID: 27285760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy.
    Hasan S; Mahmud Z; Hossain M; Islam S
    Mol Biol Rep; 2024 Oct; 51(1):1069. PubMed ID: 39424705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
    Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
    Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
    Wang Y; Chen L; Bao Z; Li S; You G; Yan W; Shi Z; Liu Y; Yang P; Zhang W; Han L; Kang C; Jiang T
    Oncol Rep; 2011 Nov; 26(5):1173-80. PubMed ID: 21887474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.